Ivabradine in Hemodialysed Patients With Increased Heart Rate
Ivabradine in Hemodialysed Patients With Increased Heart Rate
A significant association between resting heart rate (HR) and both all-cause mortality and
 cardiovascular mortality has been demonstrated in numerous epidemiologic studies for both the
 general population and for patients with cardiovascular disease.

 Cardiac disease is the leading cause of death among hemodialysis (HD) patients a recent study
 reported that the 48-hr mean HR is an independent predictor of cardiovascular events in
 normotensive hemodialysis patients.

 Ivabradine, a pure HR lowering agent,acting on If current inhibition has proven beneficial
 antianginal effects and mortality reduction linked to HR reduction in ischemic patients.

 Aim:

 To evaluate the safety and efficacy of ivabradine in normotensive hemodialysed patients with
 increased pre-dialysis HR (> 80 bpm)
Inclusion Criteria:

 -  Dialysis patients

 -  Sinus rhythm

 -  Pre-dialytic Heart rate > 80 bpm

 Exclusion Criteria:

 -  Atrial fibrillation/atrial flutter

 -  Heart failure

 -  Valvular disease